CureVac NV (CVAC)
2.76
+0.10
(+3.76%)
USD |
NASDAQ |
Nov 25, 10:56
CureVac Gross Profit Margin (Quarterly): 95.56% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 95.56% |
| June 30, 2024 | -182.1% |
| March 31, 2024 | -236.9% |
| December 31, 2023 | -137.5% |
| September 30, 2023 | -47.31% |
| June 30, 2023 | -241.1% |
| March 31, 2023 | -189.5% |
| December 31, 2022 | -584.4% |
| September 30, 2022 | -114.8% |
| June 30, 2022 | -111.9% |
| March 31, 2022 | -52.76% |
| Date | Value |
|---|---|
| December 31, 2021 | -69.84% |
| September 30, 2021 | -292.0% |
| June 30, 2021 | -66.98% |
| March 31, 2021 | -57.13% |
| December 31, 2020 | -17.93% |
| September 30, 2020 | 61.78% |
| June 30, 2020 | |
| March 31, 2020 | -75.54% |
| December 31, 2019 | -33.67% |
| September 30, 2019 | -538.6% |
| March 31, 2019 | -139.5% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-584.4%
Minimum
Dec 2022
95.56%
Maximum
Sep 2024
-123.9%
Average
-75.54%
Median
Mar 2020
Gross Profit Margin (Quarterly) Benchmarks
| BioNTech SE | 85.63% |
| Bayer AG | 48.94% |
| Affimed NV | -- |
| InflaRx NV | -- |
| Immatics NV | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 21.30% |
| Return on Assets | 15.24% |
| Return on Invested Capital | 21.30% |
| Profit Margin (Quarterly) | 68.44% |
| Operating Margin (Quarterly) | 74.39% |
| Return on Net Operating Assets | 32.95% |